Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$146.38 ▲ +0.85
(+0.58%)
MKT CAP: $14.88B • VOL: 831.6K
52W L $122 52W H $186
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$123
MEDIAN
$164
MEAN
$167
HIGH
$199
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE NBIX TAPE
NBIX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $177.12 | $168.34 | 2025-02-14 | $133.21 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $184.44 | $172.73 | 2025-02-06 | $137.60 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $166.87 | $161.02 | 2025-01-29 | $140.52 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $149.31 | — | 2025-01-17 | $143.45 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $128.81 | $139.06 | 2025-01-09 | $130.28 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $174.19 | $152.24 | 2024-12-18 | $127.35 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $141.99 | $147.84 | 2024-12-04 | $136.13 | -4.3% | 48% | C |